TY - JOUR
T1 - Re-evaluating the role of dacarbazine in metastatic melanoma
T2 - What have we learned in 30 years?
AU - Eggermont, Alexander M.M.
AU - Kirkwood, John M.
PY - 2004/8
Y1 - 2004/8
N2 - Since dacarbazine was approved for treating metastatic melanoma in the 1970s, numerous studies have evaluated whether different schedules and dacarbazine-based combinations improve clinical outcomes. This evidence-based review shows that combining dacarbazine with other drugs having single-agent activity and/or hormonal or immunotherapeutic compounds fails to provide clinically meaningful improvements in survival, and may increase toxicity. In patients with metastatic melanoma, dacarbazine was previously administered in cycles of multiple consecutive daily infusions per cycle. The introduction of potent antiemetics, together with concerns relating to patient comfort and clinic utilisation time, has enabled regimens involving single-dose dacarbazine, administered at the same total dose per cycle. These appear to be as effective as multiple-dose schedules, are well tolerated, and are more straightforward to administer. Single-administration dacarbazine (850-1000 mg/m2), once every 3 weeks, is currently the standard reference therapy in patients with advanced melanoma. New effective therapies are urgently needed for this treatment-refractory disease.
AB - Since dacarbazine was approved for treating metastatic melanoma in the 1970s, numerous studies have evaluated whether different schedules and dacarbazine-based combinations improve clinical outcomes. This evidence-based review shows that combining dacarbazine with other drugs having single-agent activity and/or hormonal or immunotherapeutic compounds fails to provide clinically meaningful improvements in survival, and may increase toxicity. In patients with metastatic melanoma, dacarbazine was previously administered in cycles of multiple consecutive daily infusions per cycle. The introduction of potent antiemetics, together with concerns relating to patient comfort and clinic utilisation time, has enabled regimens involving single-dose dacarbazine, administered at the same total dose per cycle. These appear to be as effective as multiple-dose schedules, are well tolerated, and are more straightforward to administer. Single-administration dacarbazine (850-1000 mg/m2), once every 3 weeks, is currently the standard reference therapy in patients with advanced melanoma. New effective therapies are urgently needed for this treatment-refractory disease.
KW - Dacarbazine
KW - DTIC
KW - Metastatic melanoma
UR - http://www.scopus.com/inward/record.url?scp=3843113670&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2004.04.030
DO - 10.1016/j.ejca.2004.04.030
M3 - Article
C2 - 15288283
AN - SCOPUS:3843113670
SN - 0959-8049
VL - 40
SP - 1825
EP - 1836
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 12
ER -